UBS lifts Royalty Pharma plc [RPRX] price estimate. Who else is bullish?

Royalty Pharma plc [NASDAQ: RPRX] jumped around 0.93 points on Wednesday, while shares priced at $31.23 at the close of the session, up 3.07%. The company report on February 15, 2024 at 7:30 AM that Royalty Pharma Reports Q4 and Full Year 2023 Results.

Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY 2023.

Compared to the average trading volume of 2.72M shares, RPRX reached a trading volume of 6033566 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Royalty Pharma plc [RPRX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RPRX shares is $42.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RPRX stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

UBS have made an estimate for Royalty Pharma plc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 14, 2022. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on May 13, 2022, representing the official price target for Royalty Pharma plc stock. Previously, the target price had yet another raise to $56, while Goldman analysts kept a Buy rating on RPRX stock.

The Average True Range (ATR) for Royalty Pharma plc is set at 0.79, with the Price to Sales ratio for RPRX stock in the period of the last 12 months amounting to 5.95. The Price to Book ratio for the last quarter was 2.14, with the Price to Cash per share for the same quarter was set at 1.10. Price to Free Cash Flow for RPRX in the course of the last twelve months was 4.62 with Quick ratio for the last quarter at 7.90.

How has RPRX stock performed recently?

Royalty Pharma plc [RPRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.55. With this latest performance, RPRX shares gained by 6.81% in over the last four-week period, additionally plugging by 5.36% over the last 6 months – not to mention a drop of -17.47% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RPRX stock in for the last two-week period is set at 67.06, with the RSI for the last a single of trading hit 72.08, and the three-weeks RSI is set at 63.95 for Royalty Pharma plc [RPRX]. The present Moving Average for the last 50 days of trading for this stock 28.59, while it was recorded at 30.16 for the last single week of trading, and 29.44 for the last 200 days.

Royalty Pharma plc [RPRX]: Deeper insight into the fundamentals

Royalty Pharma plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.90 and a Current Ratio set at 7.90.

Earnings analysis for Royalty Pharma plc [RPRX]

With the latest financial reports released by the company, Royalty Pharma plc posted 1.6/share EPS, while the average EPS was predicted by analysts to be reported at 1.27/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 26.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RPRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Royalty Pharma plc go to 3.20%.

Insider trade positions for Royalty Pharma plc [RPRX]

The top three institutional holders of RPRX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in RPRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in RPRX stock with ownership which is approximately 5.8325%.